Baird served as co-manager on this transaction.
AboutAMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) (NASDAQ-GS: AMAG) recently completed a follow-on offering of approximately 4,600,000 shares of common stock at a price of $44.00 per share, generating gross proceeds of approximately $200 million. The Company intends to use the net proceeds from the offering for general corporate purposes.
AMAG is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce with a focus on maternal health, anemia and cancer supportive care. AMAG is headquartered in Waltham, Massachusetts.
For additional information about this transaction, please contact:
- March 2015
- AMAG Pharmaceuticals, Inc.
- Target Location
- North America